State Board of Administration of Florida Retirement System lifted its stake in shares of Agios Pharmaceuticals Inc (NASDAQ:AGIO) by 11.3% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 61,221 shares of the biopharmaceutical company’s stock after acquiring an additional 6,238 shares during the quarter. State Board of Administration of Florida Retirement System owned approximately 0.11% of Agios Pharmaceuticals worth $5,007,000 at the end of the most recent reporting period.
Several other large investors also recently modified their holdings of the company. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in Agios Pharmaceuticals by 41.5% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,600 shares of the biopharmaceutical company’s stock valued at $149,000 after buying an additional 762 shares during the period. Bank of Montreal Can increased its holdings in Agios Pharmaceuticals by 74.8% during the fourth quarter. Bank of Montreal Can now owns 3,551 shares of the biopharmaceutical company’s stock valued at $203,000 after buying an additional 1,520 shares during the period. Swiss National Bank increased its holdings in Agios Pharmaceuticals by 2.3% during the fourth quarter. Swiss National Bank now owns 70,060 shares of the biopharmaceutical company’s stock valued at $4,005,000 after buying an additional 1,600 shares during the period. Wells Fargo & Company MN increased its holdings in Agios Pharmaceuticals by 2.4% during the first quarter. Wells Fargo & Company MN now owns 72,776 shares of the biopharmaceutical company’s stock valued at $5,952,000 after buying an additional 1,711 shares during the period. Finally, State of Alaska Department of Revenue purchased a new position in Agios Pharmaceuticals during the fourth quarter valued at approximately $160,000. 93.99% of the stock is currently owned by institutional investors and hedge funds.
NASDAQ AGIO opened at $88.62 on Friday. Agios Pharmaceuticals Inc has a 12-month low of $45.96 and a 12-month high of $92.17. The firm has a market capitalization of $5.12 billion, a price-to-earnings ratio of -13.13 and a beta of 1.98.
Agios Pharmaceuticals (NASDAQ:AGIO) last released its quarterly earnings results on Friday, May 4th. The biopharmaceutical company reported ($1.63) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.60) by ($0.03). Agios Pharmaceuticals had a negative return on equity of 61.70% and a negative net margin of 822.32%. The firm had revenue of $8.80 million during the quarter, compared to analysts’ expectations of $11.93 million. During the same period in the prior year, the firm posted ($1.56) earnings per share. Agios Pharmaceuticals’s revenue for the quarter was down 16.2% compared to the same quarter last year. sell-side analysts anticipate that Agios Pharmaceuticals Inc will post -6.51 EPS for the current fiscal year.
In other Agios Pharmaceuticals news, CEO David P. Schenkein sold 13,000 shares of Agios Pharmaceuticals stock in a transaction on Thursday, March 1st. The shares were sold at an average price of $81.09, for a total value of $1,054,170.00. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, insider Scott Biller sold 3,000 shares of Agios Pharmaceuticals stock in a transaction on Monday, May 7th. The stock was sold at an average price of $81.81, for a total transaction of $245,430.00. Following the completion of the transaction, the insider now directly owns 2,881 shares in the company, valued at $235,694.61. The disclosure for this sale can be found here. Insiders sold 60,900 shares of company stock worth $4,941,646 over the last ninety days. Corporate insiders own 3.02% of the company’s stock.
Several equities analysts recently issued reports on AGIO shares. ValuEngine raised shares of Agios Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Wednesday, May 2nd. UBS lowered shares of Agios Pharmaceuticals from an “outperform” rating to a “market perform” rating in a report on Wednesday, February 14th. SunTrust Banks reissued a “buy” rating and set a $101.00 price objective (up from $80.00) on shares of Agios Pharmaceuticals in a report on Thursday, February 15th. Needham & Company LLC lifted their price objective on shares of Agios Pharmaceuticals from $72.00 to $86.00 and gave the company a “buy” rating in a report on Thursday, February 15th. Finally, Credit Suisse Group set a $95.00 price objective on shares of Agios Pharmaceuticals and gave the company a “buy” rating in a report on Wednesday, April 11th. Four analysts have rated the stock with a hold rating, nine have assigned a buy rating and two have issued a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and an average price target of $91.00.
About Agios Pharmaceuticals
Agios Pharmaceuticals, Inc, a biopharmaceutical company, engages in the discovery and development of medicines for the treatment of cancer and rare genetic metabolic disorders in the United States. It is developing IDHIFA, a potent inhibitor of the mutated isocitrate dehydrogenase (IDH) 2 protein that is in Phase I/II clinical trials for patients with advanced hematologic malignancies with an IDH 2 mutation; Phase III clinical trial for patients with IDH2 mutant-positive acute myeloid leukemia (AML); Phase Ib frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase I/II frontline combination trial for patients with newly diagnosed AML.
Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.